Antibody Discovery
We tailor solutions to each project of each client.
To facilitate therapeutic antibody drug discovery, AnproTech has developed a comprehensive set of antibody discovery and screening services, including hybridoma and phage display platforms, combined with computer-aided antibody design (CAAD), molecular biology service, variable region sequencing and cloning, antibody screening and characterization. We provide custom services for humanized, conjugated and optimized antibodies with good pharmacologic characteristics and good biological efficacy within a quick schedule from target to therapeutic antibody candidates selection. The antibody humanization and optimization workflow has been shown as below:
01/
Fv Modeling
Application of Schrodinger’s equation to build up one Fv homology model and one Fv hetero model;
​
Generate an aggregation surface report;
Generate a PTM analysis report (including N-glycosylation, deamidation, oxidation and protease site analysis based on the displaying status of the amino acid on the 3D structure surface)
Generate 3D PI prediction.
04/
Second round of final humanization lead and selection
Affinity: Probelife (similar to Octect for kd detection) or a cell based assay (such as FACS, if other methods are not applicable)
Aggregation potential: DLS;
​
Thermostability: DSF;
​
Purity: CE.
02/
Humanization and optimization design
Up to 5 humanized VH and 5 humanized VL versions will be designed respectively;
​
PTMs will be removed if the antibody’s affinity and/or developability won’t be significantly affected;
​
Changes of the 3D PI and aggregation potential will be marked during the design process, If a developability issue is observed on the bench, this Information will be applied to fix the developability problem of the humanization lead;
​
The Predicted high risk T-cell epitope, B cell epitope, MHC-II epitope and antigenicity epitope will be recorded;
​
Clients will be informed about the potential complications to remove these epitopes
03/
First round of lead selection and production
DNA synthesis, cloning and transient transfection;
​
Affinity (ELISA) assay with expression medum;
​
Aggregation potential and thermos-stability raw screening (ELISAs after heating) with expression medum;
​
Production of the top 3 humanization leads and chimeric antibody (2mg each);
​
Non-specific binding assay (ELISA on Baculovirus) with in-house controls.